Your request to link to rcsb for Fructose-1,6-bisphosphatase


  • 1CNQ: fructose-1,6-bisphosphatase complexed with fructose-6-phosphate and zinc ions (10.1021/BI981112U )
  • 1EYI: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate and phosphate (r-state) (10.1021/BI000574G )
  • 1EYJ: fructose-1,6-bisphosphatase complex with amp, magnesium, fructose-6- phosphate and phosphate (t-state) (10.1021/BI000574G )
  • 1EYK: fructose-1,6-bisphosphatase complex with amp, zinc, fructose-6- phosphate and phosphate (t-state) (10.1021/BI000574G )
  • 1FBC: crystallographic studies of the catalytic mechanism of the neutral form of fructose-1,6-bisphosphatase (10.1021/BI00058A019 )
  • 1FBD: crystallographic studies of the catalytic mechanism of the neutral form of fructose-1,6-bisphosphatase (10.1021/BI00058A019 )
  • 1FBE: crystallographic studies of the catalytic mechanism of the neutral form of fructose-1,6-bisphosphatase (10.1021/BI00058A019 )
  • 1FBF: crystallographic studies of the catalytic mechanism of the neutral form of fructose-1,6-bisphosphatase (10.1021/BI00058A019 )
  • 1FBG: crystallographic studies of the catalytic mechanism of the neutral form of fructose-1,6-bisphosphatase (10.1021/BI00058A019 )
  • 1FBH: crystallographic studies of the catalytic mechanism of the neutral form of fructose-1,6-bisphosphatase (10.1021/BI00058A019 )
  • 1FBP: crystal structure of fructose-1,6-bisphosphatase complexed with fructose 6-phosphate, amp, and magnesium (10.1073/PNAS.87.14.5243 )
  • 1FJ6: fructose-1,6-bisphosphatase (mutant y57w) product/zn complex (r-state) (10.1021/BI000609C )
  • 1FJ9: fructose-1,6-bisphosphatase (mutant y57w) products/zn/amp complex (t- state) (10.1021/BI000609C )
  • 1FPB: crystal structure of the neutral form of fructose 1,6-bisphosphatase complexed with regulatory inhibitor fructose 2,6-bisphosphate at 2.6- angstroms resolution (10.1073/PNAS.89.6.2404 )
  • 1FPD: structural aspects of the allosteric inhibition of fructose-1,6- bisphosphatase by amp: the binding of both the substrate analogue 2, 5-anhydro-d-glucitol-1,6-bisphosphate and catalytic metal ions monitored by x-ray crystallography (10.1021/BI00013A020 )
  • 1FPE: structural aspects of the allosteric inhibition of fructose-1,6- bisphosphatase by amp: the binding of both the substrate analogue 2, 5-anhydro-d-glucitol-1,6-bisphosphate and catalytic metal ions monitored by x-ray crystallography (10.1021/BI00013A020 )
  • 1FPF: structural aspects of the allosteric inhibition of fructose-1,6- bisphosphatase by amp: the binding of both the substrate analogue 2, 5-anhydro-d-glucitol-1,6-bisphosphate and catalytic metal ions monitored by x-ray crystallography (10.1021/BI00013A020 )
  • 1FPG: structural aspects of the allosteric inhibition of fructose-1,6- bisphosphatase by amp: the binding of both the substrate analogue 2, 5-anhydro-d-glucitol-1,6-bisphosphate and catalytic metal ions monitored by x-ray crystallography (10.1021/BI00013A020 )
  • 1FPI: fructose-1,6-bisphosphatase (d-fructose-1,6-bisphosphate 1- phosphohydrolase) complexed with amp, 2,5-anhydro-d-glucitol-1,6- bisphosphate and potassium ions (100 mm) (10.1073/PNAS.92.19.8916 )
  • 1FPJ: fructose-1,6-bisphosphatase (d-fructose-1,6-bisphosphate 1- phosphohydrolase) complexed with amp, 2,5-anhydro-d-glucitol-1,6- bisphosphate, thallium (10 mm) and lithium ions (10 mm) (10.1073/PNAS.92.19.8916 )
  • 1FPK: fructose-1,6-bisphosphatase (d-fructose-1,6-bisphosphate 1- phosphohydrolase) complexed with thallium ions (10 mm) (10.1073/PNAS.92.19.8916 )
  • 1FPL: fructose-1,6-bisphosphatase (d-fructose-1,6-bisphosphate 1- phosphohydrolase) complexed with amp, 2,5-anhydro-d-glucitol-1,6- bisphosphate and thallium ions (10 mm) (10.1073/PNAS.92.19.8916 )
  • 1FRP: crystal structure of fructose-1,6-bisphosphatase complexed with fructose-2,6-bisphosphate, amp and zn2+ at 2.0 angstroms resolution. aspects of synergism between inhibitors (10.1073/PNAS.91.26.12482 )
  • 1FSA: the t-state structure of lys 42 to ala mutant of the pig kidney fructose 1,6-bisphosphatase expressed in e. coli
  • 1FTA: fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate, 1- phosphohydrolase) (e.c.3.1.3.11) complexed with the allosteric inhibitor amp
  • 1KZ8: crystal structure of porcine fructose-1,6-bisphosphatase complexed with a novel allosteric-site inhibitor (10.1021/JM010496A )
  • 1LEV: porcine kidney fructose-1,6-bisphosphatase complexed with an amp-site inhibitor (10.1016/S0960-894X(03)00310-X )
  • 1NUW: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate and phosphate at ph 9.6 (10.1074/JBC.M212395200 )
  • 1NUX: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, phosphate and inhibitory concentrations of potassium (200mm) (10.1074/JBC.M212395200 )
  • 1NUY: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, and phosphate (10.1074/JBC.M212395200 )
  • 1NUZ: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate and phosphate (10.1074/JBC.M212394200 )
  • 1NV0: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, phosphate and 1 mm thallium (10.1074/JBC.M212394200 )
  • 1NV1: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, phosphate and thallium (5 mm) (10.1074/JBC.M212394200 )
  • 1NV2: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, phosphate and thallium (20 mm) (10.1074/JBC.M212394200 )
  • 1NV3: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, phosphate and thallium (100 mm) (10.1074/JBC.M212394200 )
  • 1NV4: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, phosphate, edta and thallium (1 mm) (10.1074/JBC.M212394200 )
  • 1NV5: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, phosphate, edta and thallium (5 mm) (10.1074/JBC.M212394200 )
  • 1NV6: fructose-1,6-bisphosphatase complex with magnesium, fructose-6- phosphate, phosphate, edta and thallium (20 mm) (10.1074/JBC.M212394200 )
  • 1NV7: fructose-1,6-bisphosphatase complex with amp, magnesium, fructose-6- phosphate, phosphate and thallium (20 mm) (10.1074/JBC.M212394200 )
  • 1Q9D: fructose-1,6-bisphosphatase complexed with a new allosteric site inhibitor (i-state) (10.1074/JBC.M308396200 )
  • 1RDX: r-state structure of the arg 243 to ala mutant of pig kidney fructose 1,6-bisphosphatase expressed in e. coli
  • 1RDY: t-state structure of the arg 243 to ala mutant of pig kidney fructose 1,6-bisphosphatase expressed in e. coli
  • 1RDZ: t-state structure of the arg 243 to ala mutant of pig kidney fructose 1,6-bisphosphatase expressed in e. coli
  • 1YXI: r-state amp complex reveals initial steps of the quaternary transition of fructose-1,6-bisphosphatase (10.1074/JBC.M501011200 )
  • 1YYZ: r-state amp complex reveals initial steps of the quaternary transition of fructose-1,6-bisphosphatase (10.1074/JBC.M501011200 )
  • 1YZ0: r-state amp complex reveals initial steps of the quaternary transition of fructose-1,6-bisphosphatase (10.1074/JBC.M501011200 )
  • 2F3B: mechanism of displacement of a catalytically essential loop from the active site of fructose-1,6-bisphosphatase (10.1021/BI400532N )
  • 2F3D: mechanism of displacement of a catalytically essential loop from the active site of fructose-1,6-bisphosphatase (10.1021/BI400532N )
  • 2FBP: structure refinement of fructose-1,6-bisphosphatase and its fructose 2,6-bisphosphate complex at 2.8 angstroms resolution (10.1016/0022-2836(90)90329-K )
  • 2FHY: structure of human liver fpbase complexed with a novel benzoxazole as allosteric inhibitor (10.1016/J.BMCL.2006.01.015 )
  • 2FIE: structure of human liver fbpase complexed with potent benzoxazole allosteric inhibitors (10.1016/J.BMCL.2006.01.014 )
  • 2FIX: structure of human liver fbpase complexed with potent benzoxazole allosteric inhibitiors (10.1016/J.BMCL.2006.01.014 )
  • 2JJK: fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate -1-phosphohydrolase) (e.c.3.1.3.11) complexed with a dual binding amp site inhibitor (10.1016/J.BMCL.2008.06.103 )
  • 2QVU: porcine liver fructose-1,6-bisphosphatase cocrystallized with fru-2,6- p2 and mg2+, i(t)-state (10.1074/JBC.M707302200 )
  • 2QVV: porcine liver fructose-1,6-bisphosphatase cocrystallized with fru-2,6- p2 and zn2+, i(t)-state (10.1074/JBC.M707302200 )
  • 2VT5: fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate -1-phosphohydrolase) (e.c.3.1.3.11) complexed with a dual binding amp site inhibitor (10.1016/J.BMCL.2008.06.103 )
  • 2WBB: fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate-1- phosphohydrolase) (e.c.3.1.3.11) complexed with an amp site inhibitor (10.1016/J.BMCL.2009.11.093 )
  • 2WBD: fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate-1- phosphohydrolase) (e.c.3.1.3.11) complexed with an amp site inhibitor (10.1016/J.BMCL.2009.11.093 )
  • 2Y5K: orally active aminopyridines as inhibitors of tetrameric fructose 1,6-bisphosphatase (10.1016/J.BMCL.2011.04.044 )
  • 2Y5L: orally active aminopyridines as inhibitors of tetrameric fructose 1,6-bisphosphatase (10.1016/J.BMCL.2011.04.044 )
  • 3A29: crystal structure of human liver fbpase in complex with tricyclic inhibitor (10.1016/J.BMCL.2009.08.081 )
  • 3FBP: structure refinement of fructose-1,6-bisphosphatase and its fructose 2,6-bisphosphate complex at 2.8 angstroms resolution (10.1016/0022-2836(90)90329-K )
  • 3KBZ: crystal structure of human liver fbpase in complex with tricyclic inhibitor 6 (10.1016/J.BMCL.2009.12.056 )
  • 3KC0: crystal structure of human liver fbpase in complex with tricyclic inhibitor 10b (10.1016/J.BMCL.2009.12.056 )
  • 3KC1: crystal structure of human liver fbpase in complex with tricyclic inhibitor 19a (10.1016/J.BMCL.2009.12.056 )
  • 4FBP: conformational transition of fructose-1,6-bisphosphatase: structure comparison between the amp complex (t form) and the fructose 6- phosphate complex (r form) (10.1021/BI00232A007 )
  • 4GBV: crystal structure of amp complexes of porcine liver fructose-1,6- bisphosphatase mutant a54l with 1,2-ethanediol as cryo-protectant
  • 4GBW: crystal structure of amp complexes of porcine liver fructose-1,6- bisphosphatase mutant a54l with 1,2-propanediol as cryo-protectant
  • 4GWS: crystal structure of amp complexes of porcine liver fructose-1,6- bisphosphatase with filled central cavity
  • 4GWU: crystal structure of fru 2,6-bisphosphate complexes of porcine liver fructose-1,6-bisphosphatase with filled central cavity
  • 4GWW: crystal structure of product complexes of porcine liver fructose-1,6- bisphosphatase with blocked subunit pair rotation
  • 4GWX: crystal structure of product complexes of porcine liver fructose-1,6- bisphosphatase with restrained subunit pair rotation
  • 4GWY: crystal structure of amp complexes of porcine liver fructose-1,6- bisphosphatase with blocked subunit pair rotation
  • 4GWZ: crystal structure of amp complexes of porcine liver fructose-1,6- bisphosphatase with restrained subunit pair rotation
  • 4GX3: product complexes of porcine liver fructose-1,6-bisphosphatase with mutation r22m reveal a t-state conformation
  • 4GX4: amp complexes of porcine liver fructose-1,6-bisphosphatase with mutation r22m
  • 4GX6: amp complexes of porcine liver fructose-1,6-bisphosphatase with mutation e192q
  • 4H45: product complexes of porcine liver fructose-1,6-bisphosphatase with mutation e192q
  • 4H46: crystal structure of amp complexes of nem modified porcine liver fructose-1,6-bisphosphatase
  • 4KXP: crystal structure of amp complexes of porcine liver fructose-1,6- bisphosphatase mutant i10d in t-state (10.1021/BI400532N )
  • 4MJO: human liver fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate, 1-phosphohydrolase) (e.c.3.1.3.11) complexed with the allosteric inhibitor 3 (10.1021/CB4007002 )
  • 5FBP: crystal structure of the neutral form of fructose-1,6-bisphosphatase complexed with the product fructose 6-phosphate at 2.1-angstroms resolution (10.1073/PNAS.88.8.2989 )
  • 5LDZ: quadruple space group ambiguity due to rotational and translational non-crystallographic symmetry in human liver fructose-1,6- bisphosphatase (10.1107/S2059798316016715 )
  • 5PZQ: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 2-(4-methoxyphenyl)furan-3,4-dicarboxylic acid
  • 5PZR: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[3-[3-[(3-chlorophenyl) sulfonylcarbamoylamino]propoxy]propyl]urea
  • 5PZS: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[6-[(3-chlorophenyl) sulfonylcarbamoylamino]hexyl]urea
  • 5PZT: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(3-ethyl-4-phenylphenyl)sulfonylurea
  • 5PZU: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor [5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-yl]phosphonic acid
  • 5PZV: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromopyridin-2-yl)-3-(4-chlorophenyl)sulfonylurea
  • 5PZW: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[5-[(3-chlorophenyl) sulfonylcarbamoylamino]pentyl]urea
  • 5PZX: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-methoxy-3-(2-methylpropyl) phenyl]sulfonylurea
  • 5PZY: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(2-chlorophenyl)sulfonylurea
  • 5PZZ: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(3,4-dichlorophenyl)sulfonylurea
  • 5Q00: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 2-[3-[(5-bromo-1,3-thiazol-2-yl)carbamoylsulfamoyl]-1-methylindol-7- yl]oxyacetamide
  • 5Q01: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-(4,5-dichloro-2-methylpyrazol-3- yl)oxyphenyl]sulfonylurea
  • 5Q02: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(1,2-oxazol-3-yl)thiophen-2- yl]sulfonylurea
  • 5Q03: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(2-methylpropyl)thiophen-2- yl]sulfonylurea
  • 5Q04: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-5-chlorothiophen-2-yl)sulfonyl-3-(5-bromo-1,3-thiazol-2- yl)urea
  • 5Q05: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(2-methoxyethyl)-4-methylthiophen- 2-yl]sulfonylurea
  • 5Q06: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-(2-methyl-1,3-thiazol-4-yl) phenyl]sulfonylurea
  • 5Q07: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-6-morpholin-4-ylpyridin-2-yl)-3-[5-(2-methoxyethyl)-4- methylthiophen-2-yl]sulfonylurea
  • 5Q08: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(1-benzothiophen-3-ylsulfonyl)-3-(5-bromo-1,3-thiazol-2-yl)urea
  • 5Q09: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-[4-bromo-6-(carbamoylamino)pyridin-2-yl]-3-[5-(2-methoxyethyl)-4- methylthiophen-2-yl]sulfonylurea
  • 5Q0A: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(5-cyanopyrazin-2-yl)-3-[3-(difluoromethoxy)phenyl]sulfonylurea
  • 5Q0B: human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, e.c.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-3-methyl-1,2-thiazol-5-yl)-3-(3-methylphenyl)sulfonylurea
  • 5ZWK: crystal structure of human liver fructose-1,6-bisphoaphatase complex with fructose-1,6-bisphophate and amp
  • 6LS5: structure of human liver fbpase complexed with covalent allosteric inhibitor (10.1021/ACS.JMEDCHEM.0C00699 )
  • 6LW2: the n-arylsulfonyl-indole-2-carboxamide-based inhibitors against fructose-1,6-bisphosphatase (10.1021/ACS.JMEDCHEM.0C00726 )
  • 7C9Q: crystal structure of human liver fructose-1,6-bisphoaphatase complex with mg2+ and amp
  • 7CVH: human fructose-1,6-bisphosphatase 1 in complex with geranylgeranyl diphosphate
  • 7CVN: the n-arylsulfonyl-indole-2-carboxamide-based inhibitors against fructose-1,6-bisphosphatase
  • 7CWE: human fructose-1,6-bisphosphatase 1 in apo r-state